Sanofi and GlaxoSmithKline say their COVID-19 vaccine triggers a strong immune response, bolstering the late-comer program's potential as a booster shotBusiness Insider • 05/17/21
Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From HillhouseSeeking Alpha • 05/16/21
CureVac-GSK's Second-Gen COVID-19 Vaccine Candidate Shows Encouraging Action Against Variants In Animal StudyBenzinga • 05/13/21
GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19GlobeNewsWire • 05/07/21
GlaxoSmithKline plc (GSK) CEO Emma Walmsley on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/28/21
GlaxoSmithKline emerges as unlikely loser of COVID-19 pandemic – but will a return to normality be enough to sort out trouble?Proactive Investors • 04/28/21
GlaxoSmithKline Q1 Profit, Sales Decline As COVID-19 Vaccination Delay Other Treatments; Backs 2021 OutlookBenzinga • 04/28/21
GlaxoSmithKline pins hopes on return to normality as quarterly turnover slidesProactive Investors • 04/28/21
GlaxoSmithKline to drop quarterly results as Elliot presence signals it's time for changeProactive Investors • 04/27/21
Lloyds, GSK and Sainsbury's among mid-week reporters, Apple and Facebook earnings eyed alongside the FedProactive Investors • 04/27/21